public BRAFV600EKNotDetectedPapillaryThyroidResult()
{
YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Comment = "False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If this test was performed on a " +
"small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical specimen is recommended.";
this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and accounts for " +
"approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has been found to play " +
"a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC’s harbor a point mutation in codon 600 of the BRAF gene, resulting in " +
"the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein kinase, and thus, the " +
"RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and for risk stratification in order to guide " +
"clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations occur almost exclusively in PTC. This " +
"characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology or fine needle aspirates. Furthermore, PTC’s " +
"that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including extrathyroidal extension, lymph node metastasis, high-risk " +
"histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of the patient’s BRAF gene status may therefore confer important " +
"prognostic information and allow for more individualized treatment of patients with PTC. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " +
"by high resolution capillary electrophoresis.";
this.m_References = BRAFV600EKResult.PapillaryThyroidReference;
}
public BRAFV600EKNotDetectedPapillaryThyroidResult()
{
YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Comment = "False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If this test was performed on a " +
"small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical specimen is recommended.";
this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and accounts for " +
"approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has been found to play " +
"a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC's harbor a point mutation in codon 600 of the BRAF gene, resulting in " +
"the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein kinase, and thus, the " +
"RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and for risk stratification in order to guide " +
"clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations occur almost exclusively in PTC. This " +
"characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology or fine needle aspirates. Furthermore, PTC's " +
"that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including extrathyroidal extension, lymph node metastasis, high-risk " +
"histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of the patient's BRAF gene status may therefore confer important " +
"prognostic information and allow for more individualized treatment of patients with PTC. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " +
"by high resolution capillary electrophoresis.";
this.m_References = BRAFV600EKResult.PapillaryThyroidReference;
}
public BRAFV600EKDetectedPapillaryThyroidResult()
{
YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Comment = "This result indicates that the patient has a papillary thyroid carcinoma that may exhibit a more " +
"aggressive clinical behavior.";
this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and " +
"accounts for approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " +
"has been found to play a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC’s harbor a point mutation in codon 600 " +
"of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " +
"the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and " +
"for risk stratification in order to guide clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations " +
"occur almost exclusively in PTC. This characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology " +
"or fine needle aspirates. Furthermore, PTC’s that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including " +
"extrathyroidal extension, lymph node metastasis, high-risk histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of " +
"the patient’s BRAF gene status may therefore confer important prognostic information and allow for more individualized treatment of patients with PTC. High " +
"resolution capillary electrophoresis detected a 107-base product indicative of a BRAFV600E/K mutation, thus indicating that the patient has a PTC that may " +
"exhibit a more aggressive clinical behavior.";
this.m_References = BRAFV600EKResult.PapillaryThyroidReference;
}
public BRAFV600EKDetectedPapillaryThyroidResult()
{
YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Comment = "This result indicates that the patient has a papillary thyroid carcinoma that may exhibit a more " +
"aggressive clinical behavior.";
this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and " +
"accounts for approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " +
"has been found to play a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC's harbor a point mutation in codon 600 " +
"of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " +
"the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and " +
"for risk stratification in order to guide clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations " +
"occur almost exclusively in PTC. This characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology " +
"or fine needle aspirates. Furthermore, PTC's that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including " +
"extrathyroidal extension, lymph node metastasis, high-risk histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of " +
"the patient's BRAF gene status may therefore confer important prognostic information and allow for more individualized treatment of patients with PTC. High " +
"resolution capillary electrophoresis detected a 107-base product indicative of a BRAFV600E/K mutation, thus indicating that the patient has a PTC that may " +
"exhibit a more aggressive clinical behavior.";
this.m_References = BRAFV600EKResult.PapillaryThyroidReference;
}
